Dominique Guenot has her expertise in developing preclinical studies to propose new drug combinations in order to improve cancer response to treatment, restrain metastasis dissemination and resistance. Her models are ectopic as well as orthotopic xenografts in immune-deficient mice. Such new drug associations have allowed a phase I study for solid refractory pediatric cancers (RAPIER, EUDRAC N° 2010-022329-13; Pencreach et al. 2009). Besides preclinical studies, her team also seeks to clarify the cellular mechanisms of action of the drug combinations in order to improve the specificity of action of the drugs and find new potential therapeutic targets.